Fax: (626) 301-8978
Predictors of avascular necrosis of bone in long-term survivors of hematopoietic cell transplantation
Article first published online: 17 JUN 2009
Copyright © 2009 American Cancer Society
Volume 115, Issue 18, pages 4127–4135, 15 September 2009
How to Cite
Campbell, S., Sun, C.-L., Kurian, S., Francisco, L., Carter, A., Kulkarni, S., Parker, P., Karanes, C., Forman, S. J. and Bhatia, S. (2009), Predictors of avascular necrosis of bone in long-term survivors of hematopoietic cell transplantation. Cancer, 115: 4127–4135. doi: 10.1002/cncr.24474
- Issue published online: 4 SEP 2009
- Article first published online: 17 JUN 2009
- Manuscript Accepted: 31 DEC 2008
- Manuscript Revised: 26 NOV 2008
- Manuscript Received: 11 SEP 2008
- National Institutes of Health. Grant Number: R01CA078938
- Lymphoma/Leukemia Society Scholar Award. Grant Number: 2191-02
- avascular necrosis;
- graft-versus-host disease;
- hematopoietic cell transplantation;
- immunosuppressive agents
Avascular necrosis (AVN) is a debilitating condition reported after chronic steroid use. The purpose of this study was to describe the magnitude of risk in individuals who survived ≥1 years after hematopoietic cell transplantation (HCT), and to investigate the role of immunosuppressive agents such as prednisone, tacrolimus (FK506), mycophenolate mofetil (MMF), and cyclosporine (CSA) in the development of AVN after HCT.
Using a retrospective study design, the authors followed 1346 eligible patients for the development of AVN. Cumulative incidence was calculated taking into consideration competing risk from death and disease recurrence. Cox proportional regression techniques were used to identify associated risk factors.
The median age at HCT was 34 years (range, 7 months-69 years), and median length of follow-up for those surviving was 8.2 years. Seventy-five patients developed AVN of 160 joints. The cumulative incidence of AVN at 10 years was 2.9% after autologous HCT, 5.4% after allogeneic matched related donor HCT, and 15% after unrelated donor HCT (P < .001 compared with autologous HCT recipients). For allogeneic transplant recipients, male sex (relative risk [RR], 2.1; 95% confidence interval [95% CI], 1.1-4.0); presence of chronic graft-versus-host disease (RR, 2.2); and exposure to CSA, FK506, prednisone, and MMF rendered patients at increased risk, especially in patients with a history of exposure to ≥3 drugs (RR, 9.2; 95% CI, 2.42-35.24).
Future studies examining the pathogenetic mechanism underlying AVN should help develop targeted interventions to prevent this chronic debilitating condition. Cancer 2009. © 2009 American Cancer Society.